Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus.

We aimed to investigate the effects of asprosin on diabetes with a focus on serum glucose, irisin, ghrelin, leptin levels and hepatic levels of triglycerides (TG), cholesterol, low-density lipoprotein (LDL). Asprosin (10 µg/kg) was administered intraperitoneally four times at 3-day intervals and then blood and hepatic parameters above mentioned were investigated in control and diabetic mice. The administration of asprosin increased blood glucose level in healthy animals ( Our novel findings implicate that asprosin may be a target molecule in preventing the development and complications of diabetes.